Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma
Open Access
- 20 January 2015
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 117 (3) , 444-449
Abstract
Objective: To perform a phase II study evaluating a combination of gemcitabine and cisplatin in a population of patients with squamous cell carcinoma ( SCC ) of the penis and unresected locoregional lymph nodes and/or distant metastases, who had a poor prognosis with no standard of chemotherapy. Patients and Methods: Eligible patients had histologically confirmed SCC of the penis with unresected locoregional lymph nodes and/or distant metastases, at initial diagnosis or at relapse, and measurable disease as defined by R esponse E valuation C riteria in S olid T umors ( RECIST ) criteria. Patients were treated with a combination of gemcitabine 1250 mg/m 2 on day 1 over 30 min and cisplatin 50 mg/m 2 on day 1 over 1 h, every 2 weeks. The primary endpoint was the objective response rate; secondary endpoints were time to progression ( TTP ) and overall survival ( OS ). Results: In all, 25 patients were included in the first phase of the study between February 2004 and January 2010 and received a median of five cycles. For the intent‐to‐treat population, two patients (95% confidence interval [ CI ] 0.98–26.0) presented an objective response and 13 patients (52%) had stable disease (95% CI 35.5–76.8). The median TTP was at 5.48 months (95% CI 2.40–11.73). After a median follow‐up of 26.97 months (95% CI 17.77, not reached), nine patients were still alive. The median OS and 2‐year OS rate were respectively estimated at 14.98 months (95% CI 9.76–32.9) and 39.32% (95% CI 19.15–59.03). Eleven patients had a serious adverse event (44%), 24% being relied to chemotherapy. Conclusion: Every 2 weeks' administration of the combination of gemcitabine and cisplatin showed non‐significant responses in patients with unresected locoregional or metastatic penile SCC . Despite manageable side‐effects, this combination cannot be recommended as a standard of care, due to disappointing response rates seen in this negative study. Further regimens should be explored to improve the OS of these patients with poor prognosis.Keywords
This publication has 32 references indexed in Scilit:
- Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)British Journal of Cancer, 2013
- Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penisBJU International, 2012
- Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal functionEuropean Journal of Cancer, 2012
- Proof of Activity of Anti–Epidermal Growth Factor Receptor–Targeted Therapy for Relapsed Squamous Cell Carcinoma of the PenisJournal of Clinical Oncology, 2011
- Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II StudyJournal of Clinical Oncology, 2010
- Anatomical Mapping of Lymphatic Drainage in Penile Carcinoma with SPECT-CT: Implications for the Extent of Inguinal Lymph Node DissectionEuropean Urology, 2008
- A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)Annals of Oncology, 2008
- Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment StrategyThe Oncologist, 2008
- RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcomaEuropean Journal of Cancer, 2005
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989